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The flood of genome-wide data generated by high-throughput technologies currently provides biol-
ogists with an unprecedented opportunity: to manipulate, query, and reconstruct functional molec-
ular networks of cells. Here, we outline three underlying principles and six strategies to infer
network models from genomic data. Then, using cancer as an example, we describe experimental
and computational approaches to infer ‘‘differential’’ networks that can identify genes and
processes driving disease phenotypes. In conclusion, we discuss how a network-level under-
standing of cancer can be used to predict drug response and guide therapeutics.Cells contain a vast array of molecular structures that come
together to form complex, dynamic, and plastic networks. The
recent development of high-throughput, massively parallel tech-
nologies has provided biologists with an extensive, although still
incomplete, list of these cellular parts. The emerging challenge
over the next decade is to systematically assemble these
components into functional molecular and cellular networks
and then to use these networks to answer fundamental ques-
tions about cellular processes and how diseases derail them.
For example, how do these cellular components come together
to robustly maintain homeostasis, process exogenous and
endogenous signals, and then coordinate responses? How do
genetic aberrations disrupt the regulatory network and manifest
in disease, such as cancer? In this Perspective, we reason that,
even with a partial understanding of molecular networks, biolo-
gists are currently poised to understand how networks are de-
regulated in cancer cells and then predict how these networks
might respond to drugs.
Quantitative biophysical network models encompassing
a small number of components have made enormous contribu-
tions to our understanding of cellular networks. However, in
this Perspective, we focus on deriving network models at a large
systems scale from high-throughput data, using ‘‘data-driven
network inference.’’ In this process, a set of modeling assump-
tions are defined, such as ‘‘genetic aberrations alter normal
cellular regulation and drive tumor proliferation.’’ Then, data
are used to derive a specific model, such as specifying for
each tumor, which typically harbors many aberrant genes, which
particular genes drive proliferation. In the end, a ‘‘good’’ model of
biological networks should be able to predict the behavior of the
network under different conditions and perturbations and,
ideally, even help us to engineer a desired response. For
example, where in the molecular network of a tumor should we
perturb with drug to reduce tumor proliferation or metastasis?864 Cell 144, March 18, 2011 ª2011 Elsevier Inc.Such a global understanding of networks can have transforma-
tive value, allowing biologists to dissect out the pathways that
go awry in disease and then identify optimal therapeutic strate-
gies for controlling them.
To illustrate the potential impact of global models, we note
that the effect of a cancer drug is often hard to predict because
crosstalk and feedback are still poorly mapped in most
signaling pathways. For example, the mammalian target of
rapamycin (mTOR) is critical for cell growth, and its activity is
aberrant in most cancers; hence, it was expected to be
a good therapeutic target. Nevertheless, it shows poor results
in clinical trials. This deviation from our expectations may be
due to feedback and crosstalk between the Akt/mTOR and
the extracellular signal-regulated kinase (ERK) pathways (Carra-
cedo et al., 2008). Inhibition of mTOR releases feedback inhibi-
tion of the receptor tyrosine kinases, which can activate both
ERK and Akt (O’Reilly et al., 2006) and subsequently increase
cell proliferation.
For targeted therapy to succeed, a global view of the inter-
connectivity of signaling proteins and their influences is critical.
In this Perspective, we consider the current state and potential
future of data-driven computational approaches to network
inference, with an emphasis on applications to cancer. We will
describe three principles underlying molecular networks
and inferring these from data. These principles are matched
to current experimental capabilities and will need revamping
as technological leaps produce new types of data (e.g., more
quantitative data and with real-time dynamics). We then
consider six promising experimental-computational strategies
for constructing network-level models. Though not exhaustive,
these principles and strategies illustrate fruitful directions in
network biology and will hopefully stimulate discussion and
experimentation among computational and experimental
biologists.
Principle 1: Molecular Influences Generate Statistical
Relations in Data
Network biology has been empowered bygenomics technologies
that enable the simultaneous measurement of thousands of
molecular species. Such data offer a global unbiased view of the
entire system, which in turn necessitates computation and statis-
tics. The key underlying assumption frequently used for inferring
networks from genomic data is that influences and interactions
between biological entities generate statistical relations in the
observed data. For example, if protein A induces expression of
protein B, thenwe expect to see high levels of protein Bwhenever
levels or specific molecular states of its activator A are high. The
reverse of this logic is that statistical correlation between protein
states indicates a potential interaction between them. In a data-
driven manner, a computer can comprehensively test millions of
such hypotheses in seconds and provide a statistical score for
each candidate molecular interaction or influence. For example,
one can test the statistical association between the DNA copy
number of a candidate regulator and gene expression of a target
for each locus and gene in the genome (see Strategy 4).
Various statistical frameworks have been successfully applied
to network inference (Basso et al., 2005; Bonneau et al., 2007;
Friedman et al., 2000); the commonality between the frameworks
is that they model a target’s behavior as a function of its regula-
tors and search for the most predictive regulator set. For
example, Bayesian networks were used to reconstruct detailed
signaling pathway structures in human T cells using only the
concentration of phosphoproteins simultaneously measured in
individual cells (Sachs et al., 2005). Based solely on this data,
this network analysis discovered the majority of known influ-
ences between the measured signaling components without
prior knowledge of any pathways. Moreover, the analysis
uncovered a new point of crosstalk, which was confirmed
experimentally.
The same computational approach and mathematical
formulae correctly reconstructed yeast metabolic networks
from gene expression data (Pe’er et al., 2001). Together, these
studies demonstrate the universal nature of statistical depen-
dencies; the same formalism can be used to reconstruct yeast
metabolic networks from gene expression data and mammalian
signaling networks from phosphoprotein abundances.
Mathematical models of molecular networks have been
derived from basic biochemical principles for decades, combin-
ing chemical reaction equations into a quantitative model. For
example, Michaelis Menten equations are frequently used to
model transcription factor binding to DNA. Nevertheless, most
contemporary data sets lack the quantitative and statistical
power to resolve such models, even for small networks. Data-
driven approaches typically necessitate hundreds of samples
to gain the statistical power to resolve even a partial qualitative
map of molecular interactions. Data requirements are highly
dependent on the number of components modeled, the mathe-
matical complexity of the equations representing the molecular
interactions, and the effect size of the influences themselves.
Thus, at the heart of data-driven modeling is finding the sweet
spot in the tradeoff between more realistic (e.g., chemical reac-
tion equations) and simpler models that can be inferred more
robustly from data (e.g., linear regression).One option is to build qualitative, rather than quantitative,
models. These models can identify qualitative features such as
‘‘Mek (mitogen-activated protein kinase) activates Erk’’ or that
‘‘Met4 and Met28 are required together to induce sulfur metab-
olism.’’ If quantitative modeling is important for the problem at
hand, linear regression models provide a robust alternative to
nonlinear models (e.g., target gene expression is a linear combi-
nation of its transcription factors). Although nonlinear relations
frequently occur in biology, linear regression models are more
robust, and thus they often give better results, even when the
underlying model is nonlinear. A detailed molecular model that
is exhaustive in its molecular species and in the modeling of their
interactions remains beyond our reach for the near future.
A powerful strategy in systems biology is to abstract and
simplify models. In the ‘‘module-network’’ approach (Segal
et al., 2003), genes are grouped into modules that are assumed
to share a regulatory program. The rationale for this grouping is
based on numerous examples in which the same regulatory
circuits coordinate activation or repression of groups of genes
that are involved in the same process (e.g., the entire ribosome
complex is regulated by common transcription factors). By pool-
ingmany similar genes together, themodule-network framework
significantly increases the statistical power to identify regulatory
influences (Litvin et al., 2009).
Principle 2: Networks Are Not Fixed: The Role of Context
and Dynamics
Molecular networks are not static; rather, they exhibit dynamic
adaptations in response to both internal states and external
signals. Influences that determine network context can be
divided into four categories. (1) Genetic background strongly
determines network behavior and gives rise to significant
differences across individuals (and even cells in the special
case of cancer). (2) Cell lineages have dramatically different
network structures because of epigenetic changes and differen-
tial expression of genes. (3) Tissue milieu can reprogram
networks and their behaviors, as stromal cells do for tumors.
(4) Exogenous signals, such as nutrients and other chemicals,
affect networks (Figure 1). Ultimately, health or disease emerges
from an individual’s integration of internal and external cues.
In cancer, context can have a profound impact on how
patients respond to therapies. For example, in recent clinical
trials of a new generation of rationally targeted therapies (e.g.,
Gleevec, Herceptin, and BRAF inhibitors for chronic myeloge-
nous leukemia, breast cancer, and melanoma, respectively),
even patients that share the targeted mutation and tumor type
displayed substantially variable responses to the drugs (Sharma
et al., 2010a). In addition, in another recent trial (i.e., phase II),
a therapy was extremely effective at reversing tumors in meta-
static melanoma patients carrying the oncogenicBRAFmutation
(Flaherty et al., 2010), in which this drug effectively shuts down
the ERK pathway that is critical for this cancer. Strikingly,
however, the same drug leads to the activation of the ERK
pathway in cells with wild-type BRAF (Poulikakos et al., 2010),
potentially promoting tumors in these cells.
To gauge such network activity, response, and potential, ex-
periments must deliberately perturb the cell. For example, blood
cells from acute myeloid leukemia patients could not beCell 144, March 18, 2011 ª2011 Elsevier Inc. 865
Figure 1. Differential Networks Explain Phenotypic Variation across
Contexts
The function of a molecular network is determined by context: genetics, tissue
type, environment (e.g., nutrients), cell-cell communication, and small mole-
cules. These influences combine to determine the phenotypic response. The
‘‘differential network’’ (colored nodes and edges) models the essential
components that determine how and why a phenotypic response will vary
between contexts.differentiated fromhealthycellswhenonly thebasal levelsofphos-
phorylation of key signalingmoleculesweremeasured.Onlywhen
the samples were interrogated with growth factors and cytokines
did the resulting signaling profiles correlate with tumor genetics,
drug response, anddiseaseoutcome (Irishetal., 2004).The impor-
tance of interrogation with stimuli comes into play because many
important signaling responses, such as ERK2 activation in
response to epidermal growth factor receptor (EGFR), depend
only on fold change, rather than basal protein levels that exhibit
a high degree of variance (Cohen-Saidon et al., 2009).
Cellular responses often involve multiple feedback loops and
additional complexities (see Review by Yosef and Regev on
page 886 of this issue). For example, the transcriptional
response to EGF stimulation induces feedback attenuation
factors, such as dual-specific phosphatases (DUSPs), which
shut down the same pathways that activate EGF signaling
(Amit et al., 2007). Therefore, to understand tumor network func-
tion, drug response, and the emergence of drug resistance,
tumors must be systematically interrogated with different stimuli
and drugs, followed by time series measurements. These
measurements can then be used to derive a model describing
the quantitative temporal sequence of events from the initial
detection of an input to the tumor’s response. The goal would866 Cell 144, March 18, 2011 ª2011 Elsevier Inc.be to generate a model that has a reasonable chance of being
able to predict responses to new, previously unmeasured inputs,
such as new drugs or combinations of drugs.
Principle 3: Extracting ‘‘Differential’’ Networks
Given the importance of context, a central challenge for the field
will be to collect data across multiple environments, cell types,
and genetic backgrounds using genome-wide profiling to infer
network connectivity and function in each context. Rather than
explicitly modeling all of the moving parts of a network, we
propose that it is feasible to derive models that focus on key
components by capturing the essential differences in network
wiring, function, and response between contexts (Figure 1).
A ‘‘differential-network’’ model is designed to elucidate the
following: How do a small number of changes to the network
(e.g., genetic, epigenetic) alter the function of the network? At
the center of such a model are the altered nodes (i.e., genes or
proteins), and data-driven computation can be used to: (1) iden-
tify additional components that interact with these altered
nodes; (2) qualify and quantify how these interactions are per-
turbed; and (3) model how these network perturbations continue
to propagate though additional components to generate the
phenotype of interest, such as proliferation, invasion, or drug
response. For example, Carro et al. (2010) identify C/EBPb and
STAT3 as ‘‘master’’ transcription factors for which their overex-
pression synergistically activates expression of mesenchymal
genes and subsequent tumor aggressiveness in malignant
glioma (see Strategy 3).
The network model can be significantly simplified because
only the components that play a role in the modeled response
need identification and inclusion. Importantly, the differential
network strategy does not apply only to disease. It can be
used in any context to address questions such as what is the
difference between two cell types or how does nutrient status
affect cellular behavior?
Here, we present six strategies that combine experimental and
computational approaches to generate network inference
models. Strategies 1 and 2 focus on identifying key components;
Strategies 3 and 4 focus on deriving key network components
concurrently with their regulatory influences; and Strategies 5
and 6 advance toward increasingly detailed quantitative models
of network influences.
Strategy 1: Discovery of Inherited Alleles
and Somatic Mutations
Chromosomal aberrations and mutations are a central charac-
teristic of tumor cells. Multiple genetic aberrations collectively
influence the expression of thousands of genes, altering the
pathways and processes underlying malignant behaviors. The
emergence of high-resolution copy number assays and
massively parallel sequencing technologies opens the possibility
of tracing phenotypic differences back to their genetic source.
Large-scale initiatives are currently sequencing thousands of
tumor genomes to comprehensively catalog the prevalent
sequence mutations and chromosomal aberrations underlying
each cancer type. Indeed, entire cancer genomes have already
been sequenced in dozens of tumors, revealing a surprising
degree of mutations and chromosomal aberrations in each
individual cancer (Stephens et al., 2009). On the other hand, exon
capture techniques, called exome sequencing (Ng et al., 2010),
concentrate on the 1% of coding sequence in the human
genome. This technique enables a more economical cataloging
of coding mutations in cohorts of hundreds of tumors per cancer
type. Finally, transcriptome (or RNA) sequencing identifies ex-
pressed coding and noncoding RNA mutations. Transcriptome
sequencing also reveals fusion genes created by intronic trans-
locations, which are therefore undetected by exon sequencing
techniques (Maher et al., 2009).
These large-scale sequencing projects have uncovered a
staggering diversity of genetic aberrations across tumors.
Although each individual tumor typically harbors a large number
of aberrations, only a few play a role in pathogenesis. Therefore,
distinguishing between genetic changes that promote cancer
progression (i.e., driver mutations) and neutral mutations (i.e.,
passenger) is like finding needles in haystacks.
Recurrence was a rule of thumb for copy number aberrations
(Weir et al., 2007). Thus, it was unforeseen that only a handful of
genes would recurrently be targeted by sequence mutations in
each cancer type. The current presumption is that the majority
of the driver mutations are unique to each tumor. A key unre-
solved computational challenge is, therefore, to identify the
driver mutations associated with each cancer genome. Indeed,
the identification of these drivers is required before a differen-
tial-network approach can model how the pathogenic behavior
emerges. Computational methods addressing this task are still
under development (Akavia et al., 2010; Beroukhim et al.,
2010; Carter et al., 2009).
Although recurrence may not occur at the gene level, signifi-
cant recurrence does occur at the level of pathways. For
example, in glioblastoma, the majority of tumors have mutations
in each of three signaling pathways: P53, retinoblastoma protein
1 (RB1), and rat sarcoma (RAS)/P13K (Cancer Genome Atlas
Research Network, 2008). Because these findings define path-
ways, rather than genes, as unifying explanations for tumor
progression, it is clear that finding drivers will rely on knowledge
of molecular networks.
Unfortunately, there is currently insufficient information on
pathways in existing databases. First, the majority of signaling
proteins are not associated with any known pathway. Second,
existing databases include only a small part of what is known
and typically do not take context (e.g., cell type) into account.
More sophisticated experimental and computational methods
will be needed to define and catalog the components involved
in each pathway. A promising direction is the use of systematic
experimental and computational approaches to build interaction
maps (Amit et al., 2009; Bandyopadhyay et al., 2010), which can
subsequently be used to identify key aberrant genes. For
example, an algorithm known as interactome dysregulation
enrichment analysis (IDEA) (Mani et al., 2008) uses a specially
derived context-specific molecular network to identify key aber-
rant genes in lymphoma.
Strategy 2: Discovering Key Network Components
Using RNAi
Although naturally occurring genetic alterations help to nominate
causal genes in cancer and other diseases, deliberate perturba-tion greatly facilitates causal gene identification. Taking advan-
tage of sequenced genomes, mammalian interference (RNAi)
libraries have emerged as a central tool for systematic perturba-
tion of any gene. Indeed, RNAi-based screens have proven to be
a major tool in cancer research in which cell lines are readily
available and cell proliferation and survival provide surrogates
of tumorigenesis.
In one strategy, unbiased genome-wide RNAi screens in vitro
and in vivo are used to identify candidate causative oncogenes
and tumor suppressors that affect cell proliferation or survival.
Typically, candidate genes that are found to have an aberrant
sequencemutation, copynumberalteration, orexpressionchange
in tumors are usually selected for deeper mechanistic character-
ization (Boehm et al., 2007; Ngo et al., 2010). However, one must
always keep in mind that candidate genes that are not aberrant
may be equally important to study and target therapeutically.
In a second strategy, candidate genes are first selected from
cancer genomic data sets and then validated with small-scale
RNAi screens. For example, this strategy was recently used to
identify critical genes within tumor chromosomal deletions (Ebert
et al., 2008) and for finding the small subset of genes that affect
metastasis among hundreds selectively expressed in metastatic
tumor (Bos et al., 2009).
Finally, unbiased screens can also shed light on the suscepti-
bility or resistance of specific tumors to treatment (Ho¨lzel et al.,
2010) and to find ways to enhance the effects of current thera-
pies, such as taxanes (Whitehurst et al., 2007). Indeed, these
types of findings can rapidly influence clinical research and prac-
tice. In all cases, RNAi serves as a ‘‘functional filter’’ to pinpoint
or annotate genes that affect proliferation, death, metastasis, or
any cellular processes.
Combining computationally guided experiment design with
RNAi screens has enormous untapped potential. Although
genome-wide data sets are the most comprehensive, they are
also expensive to perform at the large scale that is required to
cover all contexts. A more economical approach is to refine
our understanding with iterative cycles of experimentation and
computation. Computational hypotheses derived from one
data set are used to design the experiments for collecting the
next data set (Figure 2). For example, protein interaction maps
andmicroarray expression data were used to nominate high like-
lihood genes for characterization in an RNAi screen that dissects
interactions between influenza and its host (Shapira et al., 2009).
This approach deepened our understanding of how the virus
manipulates or is controlled by key host defenses through direct
and indirect interactions with four major host pathways.
In the cancer setting, a good network model combined with
computational inferences can suggest which gene combina-
tions, genetic background, and cell assay (e.g., proliferation,
invasion, metabolism) should be matched in searching for new
components. For example, multiple mutations must occur
together to produce a tumor (Land et al., 1983), necessitating
a combinatorial RNAi approach. However, because a large-scale
combinatorial RNAi screen is not feasible, computational selec-
tion of likely combinations renders the experiments feasible.
Additionally, although most screens are performed in a single
genetic background, in reality, the functional impact of perturba-
tion is highly dependent on genetic background: disrupting theCell 144, March 18, 2011 ª2011 Elsevier Inc. 867
Figure 2. Experimental Design for Network Inference
(A) To comprehensively characterize tumor response to a drug, we suggest profiling a cohort of genetically characterized tumors using multiple technologies,
following perturbation with small molecules and RNAi. Then, data-driven algorithms can infer differential network models from these data. The inferred models
subsequently guide the design of experiments for the next iteration of data collection.
(B) This figure illustrates how different genetic backgrounds and experiments can help to identify driver mutations and network structure. Each identifiedmutation
recurs in a subset of samples, and driver targets are identified by knockdown using RNAi or drug.expression of a gene can cause death in one cell line and have no
effect in another cell line (Luo et al., 2008). Thus, it would be useful
to select cell lines with informative genetic backgrounds. Finally,
a good model can link genes with specific biological processes
(Akavia et al., 2010) and help us efficiently extend RNAi studies
to problems of invasion, metabolism, cell-cell interactions, and
other cancer hallmarks that are poorly understood (Hanahan
and Weinberg, 2011).
Strategy 3: Statistical Identification of Dysregulated
Genes and Their Regulators
After discovering key network components, the next step is to
decipher the wiring of the network. The majority of the computa-868 Cell 144, March 18, 2011 ª2011 Elsevier Inc.tional work in this area has been through the analysis of tumor
gene expression profiles that have accumulated on the order
of tens of thousands of microarrays over the past decade. Unlike
the top-down strategies described above, here, the approach
is bottom up: first identify the differentially expressed genes
relevant to a tumor phenotype of interest, and then use these
genes to pinpoint the master regulator that brings about their
dysregulation.
Data-driven approaches (Principle 1) have been particularly
powerful at locating the dysregulated genes and regulatory rela-
tions within tumor-related pathways. Analysis of glioblastoma
gene expression profiles using ARACNE (algorithm for the recon-
struction of accurate cellular networks) (Basso et al., 2005)
revealed two master regulators of mesenchymal transformation
in malignant glioma (Carro et al., 2010): the gene module that
corresponds to the mesenchymal transformation and the tran-
scription factors most likely regulating this module (based on
mutual information between regulator and targets). Both tran-
scription factors were then confirmed experimentally.
By extending this statistical reasoning to higher dimensions,
theMINDY (modulator inference by network dynamics) algorithm
(Wang et al., 2009) could cleverly identify posttranslational acti-
vators and inhibitors ofmaster regulators. Based on the assump-
tion that high (or low) expression of such activators (or inhibitors)
would lead to increased (or reduced) coregulation of MYC with
its known targets, MINDY uncovered new posttranslational
modifiers of MYC in human B lymphocytes, and four of them
were validated using RNAi. Demonstrating the generality of the
statistical approach, the identified modifiers were found to act
by diverse mechanisms, including protein turnover, transcription
complex formation, and selective enzyme recruitment.
As we wait for the development of experimental technologies
that detect most posttranslational changes in high throughput,
thousands of existing mRNA expression data sets can benefit
from this powerful statistical approach to predict keymodulators
of regulatory activity by any biochemical mechanism. We have
thus only begun to tap into the potential of these approaches
to uncover the regulatory mechanisms that lead to tumors and
other pathogenic phenotypes. Moreover, once profiles of cancer
proteomes and their posttranslational modifications become
more readily available, these methods will be dramatically
empowered.
Strategy 4: Integrating Genotype and Gene Expression
into Causal Models
Current analysis has only scratched the surface of existing data
sets, and there is critical need for powerful computational
approaches to expose the wealth of hidden information. A prom-
ising approach is ‘‘data integration’’ that builds a model from
diverse data types (e.g., gene sequence, gene expression
profiles, and protein-protein interactions), which each shed
a different light on the underlying biology. The resulting combina-
tion is more than the sum of the parts (see the MiniReview by
Ideker et al. on page 860 of this issue). A natural integration
that captures the essence of differential networks is sequence
and expression.
For example, the CONEXIC (copy number and expression in
cancer) algorithm (Akavia et al., 2010) combines DNA copy
number with gene expression levels to identify driver mutations
and predict the processes that they alter. Themodeling assump-
tions underlying the data integration are: (1) A driver mutation
should co-vary with a gene module involved in tumorigenesis
(i.e., it assumes that the module’s expression is ‘‘modulated’’
by the driver); and (2) Expression levels of the driver control the
malignant phenotype rather than copy number (because other
mechanisms may lead to similar dysregulated expression of
the driver gene).
This approach predicted two new tumor dependencies in
melanoma and the processes that they alter. Moreover, these
predictions were then confirmed using RNAi. CONEXIC thus
uses gene expression as an intermediary to connect genotypeto phenotype, building a cascade of events from DNA, through
modulated gene expression, to tumorigenic phenotype. Anchor-
ing the model at the DNA provided support for causality of influ-
ence between driver andmodule, although this influence can still
be indirect by a cascade of unknown mechanisms.
Though such modeling approaches have only recently taken
hold in cancer genomics, these have been developing in genetic
association for a few years. Chen and colleagues identified gene
networks that are perturbed by quantitative trait loci (QTL), which
in turn lead to metabolic disease (Chen et al., 2008). A single
comprehensive computation locates the QTL, identifies how it
perturbs the molecular network, and in turn leads to variation
in disease traits. As more data types that capture the ‘‘state’’
of the network are collected (e.g., metabolite concentrations
using mass spectrometry), these differential-network (Principle
3) approaches will lead to increasingly mechanistic and causal
models of disease.
Although this strategy can be applied to any process or
disease, cancer is particularly suited for these approaches
because somatic mutations driving tumorigenesis typically
have a large impact on multiple genes and cellular processes,
and thus their effect is more easily detected. Disease genes
based on germline mutations that persist though the powerful
evolutionary filters are typically more subtle and harder to detect;
indeed, disease is frequently invoked only by the combinatorial
interaction of many genes.
As proof of concept of ‘‘personalized medicine’’ and using
yeast as a model system, CAMELOT (causal modeling with
expression linkage for complex traits) (Chen et al., 2009) inte-
grated genotype and gene expression levels (measured prior
to drug exposure) to quantitatively predict drug sensitivity.
Applying a differential network approach, a small number of
causative genes are identified and then used to build regression
models to predict drug response for each yeast strain. The
algorithm faithfully predicted both the causal genes (24/24
predictions validated) and drug response. Although epistatic
relations existed between genes, the statistical simplicity of
linear models led to more robust and accurate models from
data. We anticipate that a comparable data set from patient
tumors (including genotype, basal gene expression, and quanti-
tative drug response) could be used to rationally select each indi-
vidual patient’s drug treatment, essentially customizing and opti-
mizing patient care.
Strategy 5: Integration of Single Cell Data to Account
for Cell-to-Cell Heterogeneity
Whereas the measurements discussed thus far were taken over
population aggregates using bulk assays, most signal process-
ing occurs at the level of the individual cell. Over the past
decade, studies have repeatedly demonstrated a large degree
of heterogeneity between individual cells, even within clonal
populations. This variation arises from differences in protein
concentrations and stochastic fluctuations in biochemical reac-
tions involving molecules with low copy numbers. A common
finding is that a response appears dose dependent in bulk
assays but is actually an ‘‘all or nothing’’ response in single cells.
That is, the intensity of the single cell response remains constant
under dose, but the fraction of the cells that respond increasesCell 144, March 18, 2011 ª2011 Elsevier Inc. 869
with dose (e.g., NF-kB in response to TNFa) (Tay et al., 2010). In
these cases, there are a number of distinct subpopulations, and
no individual cell behaves in accordance with the population
average. Such subpopulations confound network inference
algorithms when two molecules exhibit statistical dependency
at the population level but actually reside in mutually exclusive
cells.
Heterogeneity of molecules at the single cell level can have
crucial functional impact. Even clonal cell lines treated with
drugs under carefully controlled conditions exhibit a large, previ-
ously unappreciated degree of variation in cell survival and other
parameters (Cohen et al., 2008). A bulk growth assay can mask
a small subpopulation of drug-resistant cells, which can later
form a drug-resistant tumor. Though much debate still exists
regarding the origins and emergence of these subpopulations,
it is clear that such populations often exist in tumors. For
example, Sharma and colleagues identified a drug-tolerant state
that can be transiently acquired and relinquished through revers-
ible epigenetic changes that occur at low frequency (Sharma
et al., 2010b). Therefore, to model drug response in tumors, it
is vital to observe the system at the single cell level and take
heterogeneity (stochastic, genetic, and microenvironment) into
account.
A unique and beneficial feature of single cell data is the simul-
taneous observation of multiple signaling proteins in each indi-
vidual cell. The stochastic variation observed across individual
cells can be harnessed as a data-rich source for network infer-
ence, in which each of many thousands of cells can be treated
as an individual sample (Sachs et al., 2005). This strategy
provides significantly more samples than are available in bulk
assays (e.g., each microarray is only a single sample).
Nevertheless, this amount of data comes with a technical
tradeoff. To identify interactions and their function, the partici-
pating signaling proteins need to be measured simultaneously
in the same sample. Typically, single cell measurement technol-
ogies are limited to a small number of simultaneous channels
(approximately four to ten channels for flow cytometry and
approximately three channels for microscopy), with microscopy
having the unique advantage of real-time tracking across space
and time. A promising emerging technology is mass spectrom-
etry-based single cell cytometry (Ornatsky et al., 2008), which
currently can measure up to 35 antibodies in a single cell, with
the potential scale up to 100. This approach will likely break
new ground by enabling the study of midscale networks in indi-
vidual cells. We hope and must rely on clever chemists, engi-
neers, and physicists to take on this important challenge of
measuring many molecular states in live, single cells over time
and space.
In the meantime, computational approaches can help bridge
the gap by: (1) pointing to a small number of key components
in a differential network, which would be valuable to analyze
at the single cell level, and (2) stitching together small, overlap-
ping subnetworks into larger network models (Sachs et al.,
2009). But there remains a need to develop methods for inte-
grating genomic data sets at the population level with single
cell measurements over small subsets of components at critical
network junctures, leading to a more accurate model of the
underlying cellular computations.870 Cell 144, March 18, 2011 ª2011 Elsevier Inc.Strategy 6: Using Perturbations to Reveal Network
Wiring
To infer network models that describe how a network responds
to stimuli, as well as through what molecular interactions and
mechanisms this sensing and response occurs, comprehensive
profiles must be measured following perturbations. We consider
three methods to perturb the system: RNAi, drugs, and natural
variation. As this strategy is still under development, this section
is more speculative.
Measuring network behavior following an RNAi perturbation
uncovers the functions of a gene and provides definitive causal
links between network components. A key strength of RNAi is
that it can be used effectively to target any desired gene.
However, RNAi also has limitations due to its slow kinetics and
potential nonspecific cellular responses (e.g., innate immune
response to double-stranded RNA, overloading of the RNAi
machinery, and off-target effects). Using RNAi-based perturba-
tions followed by comprehensive measurements, Amit et al.
(2009) recently developed a network model of transcriptional
regulation in the pathogen-sensing response. Candidate regula-
tors and a reduced signature response were first selected from
microarray data of cells stimulated with pathogens. Each candi-
date was then knocked down with RNAi, and the effect on the
signature was quantified. This strategy uncovered many new
factors involved in pathogen sensing and generated an informa-
tive network wiring diagram that revealed new crosstalk and
feedback in these pathways. This strategy and its variations
should succeed in reconstructing medium-size molecular
networks in other systems.
A second perturbation to consider is small molecules, which
often have unique and valuable properties for network modeling
and direct relevance to patient care. First, in contrast to RNAi
kinetics, the instantaneous action of small molecules allows for
accurate control of both dose and timing, leading to simpler
interpretations of its effects, without the need to consider
network adaptation. Second, small molecules can have specific
biochemical effects on proteins, leading to elimination of edges
in the network, rather than entire nodes as RNAi does. By
comprehensive monitoring of the resulting changes in the
network upon drug perturbation, we can refine network models
and, importantly, discover how pathway activation, crosstalk,
and feedback differ across individual tumors with variable levels
of drug sensitivity.
Third, variation in the DNA across individuals is a powerful
resource for studying the effects of perturbation on network
function. It is also effective for detecting regulatory interactions,
uncovering complex phenotypes, and inferring networks (Lee
et al., 2006). In contrast to deliberate and somewhat dramatic
disruption of a gene’s function through RNAi or drugs, more
subtle effects, such as the attenuation or alteration of function,
can be observed in genetically divergent individuals. Natural
variation provides us with numerous genetic alterations in
various combinations, as selected by evolution to produce func-
tional pathways. By monitoring functional pathways in action,
we can infer how network components work together under
different conditions. Each individual’s genetic variation provides
distinct information linking genotype and phenotype and helps to
explain network behavior.
What still needs to be developed is an integrated experi-
mental-computational strategy that combines stimulations and
perturbations with functional measurements from the same cells
to build network models. Variation in stimuli and environment
allows us to derive what the network is computing, and perturba-
tions to its components elucidate how the network is computing.
This suggests expanding the framework set forth by Amit and
colleagues (Amit et al., 2009) to additional dimensions, including
a time series of gene expression and proteomic measurements,
following each combination of stimuli and perturbations. Natural
variation between individuals and tumors combined with tar-
geted perturbations using RNAi or drugs will provide particularly
powerful data for deriving tumor network models.
Executing the experimental design proposed above requires
technological developments. Much of the dynamics occurs at
the level of proteins and their modifications, raising the need
for high-throughput proteomics to measure protein abundances
and activity states. Importantly, the proposed design requires
assaying a prohibitively large number of samples. To make
significant progress in the understanding of molecular networks,
there is a critical need for the development of more economical
multiplex functional assays that can measure thousands of
molecular species per sample at low sample cost. An iterative
approach, in which computational modeling with existing data
guides the selection of the next set of experiments, will provide
the most cost-effective design (Figure 2).
New experimental technologies are rapidly progressing, with
computational efforts lagging behind. For example, generating
transcriptome sequence reads is easy, but their assembly
remains challenging. To utilize the enormous potential of the
data types delineated above, significant advances in computa-
tional modeling are required. Specifically, there is need for a
transition from static and qualitative models to temporal and
quantitative models.
Future: Personalized Cancer Medicine
Networks govern fundamental processes, such as the develop-
ment of a multicellular organism from a single cell and communi-
cation between immune cells in response to a pathogen.
Fueled by technology and computation, research in the coming
decade is expected to unravel the details and principles behind
diverse molecular networks and how they compute life’s func-
tions. For example, the ongoing revolution that has enabled the
sequencing of individuals provides the first opportunities to
systematically study and explain how DNA variation results in
our phenotypic diversity. Reaching these goals, however, will
also necessitate a deeper understanding of the biophysical prin-
ciples underlying signal processing in small biological circuits
and how these come together in systems of increasing size
and complexity.
Within cancer research, systems biology is dramatically
advancing our mechanistic understanding of tumor progression
and the design of personalized therapeutics. Continued success,
however, will depend on critical advances in both experimental
andcomputationalmethods. Improvements in tools formeasure-
ment—especially mass spectrometry and cost-effective multi-
plex detection—and perturbation—especially RNAi and small
molecules—will fill in our understanding of the many molecularlayers that underlie network function. On the computational
end, the key bottleneck is the development of validated
computational methods that integrate heterogeneous data and
build differential-network models on a per tumor basis. These
methods are required to: (1) identify the genetic aberrations and
the master regulators that drive proliferation, survival, metas-
tasis, and drug resistance; (2) model the adaptive/feedback
mechanisms that thwart the efficacy of potent drugs; and (3)
predict additional target pathways for combinatorial drug treat-
ment. Based on these predictions, more data can be collected
to refine the models in iterative rounds of computation and
experiments. As three-dimensional models of cancer (Ridky
et al., 2010) continue to develop, we can also profile multiple
cell types in a tumor environment and model the interactions
between these. In short, these studies should teach us what
drives cancers and what part of the networks we should target,
both initially and after the network adapts and mutates.
Many of us believe that the ultimate solutions to minimizing
cancer reside in the regime of combinatorial patient-specific
drug therapy, immunotherapy, and gene therapy. Accurate
quantitative models of tumor networks should predict the effects
of drug perturbations and thus enable sophisticated rational
therapy with optimized dosage, timing, and drug combination
for each individual tumor. Drug combinations can address
feedback and network adaptation, ensuring shutdown of the
necessary pathways. Additionally, drug combinations can target
distinct subpopulations within a tumor.
Tumor networks are armedwith the ability to adapt and rapidly
evolve and, thus, are a powerful adversary. These need to bemet
with equally sophisticated and flexible therapy regimes that can
track these adaptations and dynamically adapt over time,
placing us several moves ahead of the tumor. Studying the emer-
gence of drug resistance both in vitro (Johannessen et al., 2010)
and in vivo can better inform methods to anticipate potential
paths of resistance. The ultimate therapies would involve
sending ‘‘networks’’ in vivo to track tumor behavior and control
the dosage and timing of drug release in response to tumor
behavior. This long-term goal should become feasible as the
fields of network biology, synthetic biology, and appropriate
drug delivery methodsmature. In the immediate future, however,
our goal should be to anticipate andmonitor real-time changes in
the tumor’s network and adapt our therapies accordingly.ACKNOWLEDGMENTS
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